The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 15, 2021
Filed:
Jan. 15, 2019
Applicant:
National Institute of Biological Sciences, Beijing, Beijing, CN;
Inventors:
Zhiyuan Zhang, Beijing, CN;
Xiaodong Wang, Beijing, CN;
Shaoqiang Huang, Beijing, CN;
Xian Jiang, Beijing, CN;
Li Li, Beijing, CN;
Zhaolan Zhang, Beijing, CN;
Jianguang Han, Beijing, CN;
Assignee:
National Institute of Biological Sciences, Beijing, Beijing, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 409/04 (2006.01); A61P 25/16 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 403/04 (2006.01); C07D 239/38 (2006.01); C07D 239/47 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 495/04 (2006.01); A61K 31/506 (2006.01); A61P 37/00 (2006.01); A61K 31/505 (2006.01); A61P 25/00 (2006.01); A61P 9/10 (2006.01); A61P 25/28 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 409/04 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61P 9/10 (2018.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 37/00 (2018.01); C07D 239/38 (2013.01); C07D 239/47 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01);
Abstract
The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.